Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration

Blood

Volumn 100, Issue 7, 2002, Pages 2341-2348

  Porcu, Pierluigi ^a,b,c   Eisenbeis, Charles F ^a,b,c   Pelletier, Ronald P ^a,b,c   Davies, Elizabeth A ^a,b,c   Baiocchi, Robert A ^a,b,c   Roychowdhury, Sameek ^a,b,c   Vourganti, Srinivas ^a,b,c   Nuovo, Gerard J ^a,b,c   Marsh, William L ^a,b,c   Ferketich, Amy K ^a,b,c   Henry, Mitchell L ^a,b,c   Ferguson, Ronald M ^a,b,c   Caligiuri, Michael A ^a,b,c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; AZATHIOPRINE; CD8 ANTIGEN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMIDINE KINASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0036785374     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0210     Document Type: Article

References (46)

1. Excerpts from United States Renal Data System 1999 Annual Report. VII. Renal transplantation: access and outcomes. Am J Kidney Dis. 1999;34:S95-S101.
2. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc. 1991;23:1101-1103.
3. Purtilo DT, Strobach RS, Okano M, Davis JR. Epstein-Barr virus-associated lymphoproliferative disorders. Lab Invest. 1992;67:5-23.
4. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13.
5. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993;342:1514-1516.
6. Swinnen LJ. Diagnosis and treatment of transplant-related lymphoma. Ann Oncol. 2000;11(suppl 1):45-48.
7. Makowka L, Nalesnik MA, Stieber A. Control of post-transplant lymphoproliferative disorders and Kaposi's sarcoma by modulation of immunosuppression. In: Good RA, Lindenlaub E, eds. The Nature, Cellular and Biochemical Basis, and Management of Immunodeficiencies. New York. NY: FK Schattauer Verlag; 1987:567-624.
8. Nalesnik MA, Locker J, Jaffe R, et al. Experience with post-transplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplant. 1992;6:249.
9. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:583-587.
10. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation. 1999;68:1517-1525.
11. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995;86:3333-3340.
12. Mamzer-Bruneel MF, Lome C, Morelon E, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol. 2000;18:3622-3632.
13. Oertel SH, Ruhnke MS, Anagnostopoulos I, et al. Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation. Transplantation. 1999;67:765-767.
14. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med. 1982;306:913-918.
15. Katz BZ, Raab-Traub N, Miller G. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J Infect Dis. 1989;160:589-598.
16. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 1989;321:1080-1085.
17. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood. 1998;92:3137-3147.
18. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder; a retrospective analysis on 32 patients. Ann Oncol. 2000;11:113-116.
19. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-1555.
20. Faller DV, Hermine O, Small T, et al. Phase I/II trial of arginine butyrate to induce viral TK gene expression in Epstein-Barr virus (EBV)-associated lymphomas [abstract]. Blood. 2000;96:577a.
21. Nuovo GJ. PCR In-Situ Hybridization: Protocols and Applications. 3rd ed. New York, NY: Lippincot-Raven Press; 1997.
22. Nuovo GJ, Morrison C, Porcu P, Caligiuri MA, Suster S. In situ determination of T-cell receptor β expression patterns. J Histochem Cytochem. 2001;49:139-145.
23. Morrison C, Porcu P, Caligiuri MA, Nuovo GJ. In situ determination of B-cell heavy chain, light chain, Bcl-2, and cyclin D1 expression patterns: methodology and clinical utility. Diagn Mol Pathol. 2001;10:171-178.
24. Burrows SR, Kienzle N, Winterhalter A, Bharadwaj M, Altman JD, Brooks A. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol. 2000;165:6229-6234.
25. Hollander M, Wolfe DA. Non-Parametric Statistical Methods, New York, NY: John Wiley and Sons; 1999.
26. Shapiro R, Nalesnik M, McCauley J, et al. Post-transplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999;68:1851-1854.
27. Caillard S, Lachat V, Moulin B. Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. Transpl Int. 2000;13:S388-S393.
28. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334:426-431.
29. Khatri VP, Baiocchi RA, Peng R, et al. Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. J Immunol. 1999;163:500-506.
30. Ambinder RF, Lemas MV, Moore S, Yang J, Fabian D, Krone C. Epstein-Barr virus and lymphoma. Cancer Treat Res. 1999;99:27-45.
31. Gratama JW, Zutter MM, Minarovits J, et al. Expression of Epstein-Barr virus-encoded growthtransformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int J Cancer. 1991;47:188-192.
32. Delecluse HJ, Kremmer E, Rouault JP, Cour C, Bornkamm G, Berger F. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am J Pathol. 1995;146:1113-1120.
33. Oudejans JJ, Jiwa M, van den Brule AJ, et al. Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual posttransplantation lymphoproliferative disorders. Am J Pathol. 1995;147:923-933.
34. Rea D, Fourcade C, Leblond V, et al. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation. 1994;58:317-324.
35. Rowe M, Niedobitek G, Young LS. Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders. Springer Semin Immunopathol. 1998;20:389-403.
36. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med. 1997;185:1605-1617.
37. Tan LC, Gudgeon N,Annels NE, et al. A reevaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol. 1999;162:1827-1835.
38. Littler E, Zeuthen J, McBride AA, et al. Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J. 1986;5:1959-1966.
39. Smith RF, Smith TF. Identification of new protein kinase-related genes in three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus. J Virol. 1989;63:450-455.
40. Chen MR, Chang SJ, Huang H, Chen JY. A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro. J Virol. 2000;74:3093-3104.
41. Gustafson EA, Chillemi AC, Sage DR, Fingeroth JD. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type I thymidine kinase. Antimicrob Agents Chemother. 1998;42:2923-2931.
42. Harrington WJ Jr, Cabral L, Cai JP, Chan-A-Sue S, Wood C. Azothymidine and interferon-α are active in AIDS-associated small non-cleaved cell lymphoma but not large-cell lymphoma. Lancet. 1996;348:833.
43. Raez L, Cabral L, Cai JP, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses. 1999;15:713-719.
44. Chadburn A, Cesarman E, Liu YF, et al. Molecular genetic analysis demonstrates that multiple post-transplantation lymphoproliferative disorders occurring in one anatomic site in a single patient represent distinct primary lymphoid neoplasms. Cancer. 1995;75:2747-2756.
45. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. BrJ Haematol. 2001;115:112-118.
46. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502-1505.